title: The impact of AD drug treatments on event-related potentials as markers of disease conversion.
abstract: This paper investigates how commonly prescribed pharmacologic treatments for Alzheimer's disease (AD) affect Event-Related Potential (ERP) biomarkers as tools for predicting AD conversion in individuals with Mild Cognitive Impairment (MCI). We gathered baseline ERP data from two MCI groups (those taking AD medications and those not) and later determined which subjects developed AD (Convert->AD) and which subjects remained cognitively stable (Stable). We utilized a previously developed and validated multivariate system of ERP components to measure medication effects among these four subgroups. Discriminant analysis produced classification scores for each individual as a measure of similarity to each clinical group (Convert->AD, Stable), and we found a large significant main Group effect but no main AD Medications effect and no Group by Medications interaction. This suggested AD medications have negligible influence on this set of ERP components as weighted markers of disease progression. These results provide practical information to those using ERP measures as a biomarker to identify and track AD in individuals in a clinical or research setting.
authors.affiliation: Department of Brain and Cognitive Sciences, 775 Library Road, University of Rochester, Rochester, NY 14627, USA. rmc@cvs.rochester.edu
authors.forename: Robert M
authors.initials: RM
authors.lastname: Chapman
authors.forename: Anton P
authors.initials: AP
authors.lastname: Porsteinsson
authors.forename: Margaret N
authors.initials: MN
authors.lastname: Gardner
authors.forename: Mark
authors.initials: M
authors.lastname: Mapstone
authors.forename: John W
authors.initials: JW
authors.lastname: McCrary
authors.forename: Tiffany C
authors.initials: TC
authors.lastname: Sandoval
authors.forename: Maria D
authors.initials: MD
authors.lastname: Guillily
authors.forename: Lindsey A
authors.initials: LA
authors.lastname: Reilly
authors.forename: Elizabeth
authors.initials: E
authors.lastname: DeGrush
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D060825:Cognitive Dysfunction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D018450:Disease Progression; D004569:Electroencephalography / Q000187:drug effects / Q000379:methods; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents
references.citation: Brain Cogn. 1995 Apr;27(3):288-310
references.pmid: 7626278
references.citation: Clin Neurophysiol. 2005 Aug;116(8):1747-53
references.pmid: 16000258
references.citation: Psychophysiology. 1981 Sep;18(5):493-513
references.pmid: 7280146
references.citation: Can J Psychol. 1981 Jun;35(2):201-12
references.pmid: 7248852
references.citation: Nature. 1964 Sep 12;203:1155-7
references.pmid: 14213667
references.citation: J Psychiatr Res. 1982-1983;17(1):37-49
references.pmid: 7183759
references.citation: Neurobiol Aging. 2011 Oct;32(10):1742-55
references.pmid: 20005599
references.citation: Neurology. 2008 May 6;70(19 Pt 2):1763-70
references.pmid: 18077800
references.citation: J Am Geriatr Soc. 2010 Feb;58(2):389-90
references.pmid: 20370868
references.citation: Phys Med Rehabil Clin N Am. 2004 Feb;15(1):205-33
references.pmid: 15029906
references.citation: Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S137-43
references.pmid: 18631990
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: Science. 1978 Dec 15;202(4373):1211-4
references.pmid: 725596
references.citation: Neuroscience. 2007 Dec 5;150(2):346-56
references.pmid: 17996378
references.citation: J Intern Med. 2004 Sep;256(3):183-94
references.pmid: 15324362
references.citation: Psychol Aging. 2001 Mar;16(1):161-76
references.pmid: 11302364
references.citation: Alzheimers Dement. 2011 May;7(3):270-9
references.pmid: 21514249
references.citation: Nature. 1964 Jul 25;203:380-4
references.pmid: 14197376
references.citation: Neurobiol Aging. 2007 Feb;28(2):194-201
references.pmid: 16430992
references.citation: J Alzheimers Dis. 2013;33(1):55-68
references.pmid: 22886016
references.citation: J Int Neuropsychol Soc. 2011 Jul;17(4):654-62
references.pmid: 21486518
references.citation: Psychophysiology. 2000 Mar;37(2):127-52
references.pmid: 10731765
references.citation: Clin Neuropharmacol. 2003 Sep-Oct;26(5):239-51
references.pmid: 14520164
references.citation: Arch Neurol. 2009 Dec;66(12):1447-55
references.pmid: 20008648
references.citation: J Nutr Health Aging. 2012;16(6):544-8
references.pmid: 22659994
references.citation: Lancet Neurol. 2010 Nov;9(11):1118-27
references.pmid: 20934914
references.citation: Clin Neuropharmacol. 2002 Jul-Aug;25(4):207-15
references.pmid: 12151908
references.citation: Brain Res. 2007 May 11;1145:108-16
references.pmid: 17320833
references.citation: J Clin Exp Neuropsychol. 1991 Nov;13(6):933-49
references.pmid: 1779032
references.citation: Neurology. 2001 May 8;56(9):1133-42
references.pmid: 11342677
references.citation: Neurology. 1984 Jul;34(7):939-44
references.pmid: 6610841
references.citation: PLoS Med. 2007 Nov 27;4(11):e338
references.pmid: 18044984
references.citation: Clin Neuropharmacol. 2001 Jan-Feb;24(1):31-42
references.pmid: 11290880
references.citation: Br J Psychiatry. 1968 Jul;114(512):797-811
references.pmid: 5662937
references.citation: Clin Neurophysiol. 2006 Mar;117(3):699-702; author reply 703-7
references.pmid: 16480923
references.citation: Brain Topogr. 1998 Fall;11(1):43-55
references.pmid: 9758391